8-K: Delcath Systems Reports Strong Q2 2025 Growth

Delcath Systems announced robust second-quarter 2025 financial results, driven by significant revenue growth from its HEPZATO KIT and a shift to net income and positive adjusted EBITDA.

Summary

• Total revenue for the second quarter ended June 30, 2025, was $24.2 million, a substantial increase from $7.8 million in the second quarter of 2024.
• HEPZATO KIT revenue reached $22.5 million, up from $6.6 million in the prior year's second quarter.
• CHEMOSAT revenue also increased to $1.7 million from $1.2 million in the second quarter of 2024.
• Gross margins improved to 86% in Q2 2025, compared to 80% in Q2 2024.
• The company reported a net income of $2.7 million for the quarter, a significant turnaround from a net loss of $13.7 million in Q2 2024.
• Non-GAAP positive adjusted EBITDA was $9.8 million, compared to a loss of $0.8 million in the second quarter of 2024.
• Cash provided by operations amounted to $7.3 million during the quarter.
• Cash and investments stood at $81.0 million as of June 30, 2025, with no debt.
• Three new U.S. centers were activated in the second quarter, bringing the total to 20 active centers, with an additional 10 centers accepting referrals.
• Delcath announced its intention to enter into a Medicaid National Drug Rebate Agreement (NDRA) to expand patient access starting July 1, 2025.
• Authorization was received from European Union and United Kingdom regulatory authorities for a clinical study of Melphalan for Injection/Hepatic Delivery System in patients with refractory metastatic colorectal cancer with liver dominant disease.
• The company updated its full-year 2025 financial guidance, projecting total CHEMOSAT and HEPZATO KIT revenue in the range of $93 million to $96 million, an increase of more than 150% over 2024.
• Full-year 2025 gross margins are expected to be in the range of 83% to 85%, with positive adjusted EBITDA and cash flow anticipated in each quarter of 2025.

Sentiment

Score: 9

Explanation: The filing reports exceptionally strong financial performance, including significant revenue growth, a shift to profitability, positive cash flow, and an optimistic outlook for the full year. The expansion of treatment centers and new clinical study authorizations further bolster positive sentiment. The only minor negative is increased expenses, which are tied to growth initiatives.

Positives

• Significant increase in total revenue to $24.2 million in Q2 2025, up from $7.8 million in Q2 2024, demonstrating strong market adoption.
• Robust growth in HEPZATO KIT revenue to $22.5 million, a substantial increase from $6.6 million, indicating successful commercialization.
• Improved gross margins to 86% from 80%, reflecting enhanced profitability per sale.
• Achieved net income of $2.7 million, a major turnaround from a $13.7 million net loss in the prior year, signaling financial health.
• Shifted to positive non-GAAP adjusted EBITDA of $9.8 million from a $0.8 million loss, indicating operational efficiency and profitability.
• Generated $7.3 million in cash from operations, strengthening liquidity.
• Maintained a strong cash and investments balance of $81.0 million with no debt, providing financial flexibility.
• Expanded U.S. active centers to 20, with 10 additional centers accepting referrals, broadening market reach.
• Initiative to expand patient access via Medicaid National Drug Rebate Agreement (NDRA) from July 1, 2025.
• Received regulatory authorization in Europe and UK for a new clinical study in metastatic colorectal cancer, indicating pipeline expansion.
• Positive physician feedback and increased confidence in HEPZATO's long-term growth prospects.
• Updated 2025 full-year revenue guidance to $93-$96 million, representing an increase of over 150% from 2024, signaling strong future expectations.
• Expectation of positive adjusted EBITDA and cash flow in each quarter of 2025, indicating sustained profitability.

Negatives

• Research and development expenses increased to $6.9 million from $3.4 million, primarily due to costs associated with expanding the clinical team and initiating new Phase 2 clinical trials.
• Selling, general and administrative expenses increased to $11.4 million from $6.8 million, driven by continued commercial expansion activities and additional personnel.

Risks

• Uncertainties relating to the company's commercialization plans and its ability to successfully commercialize the HEPZATO KIT.
• Uncertainties regarding contributions to adjusted EBITDA.
• Challenges in successfully managing the HEPZATO KIT supply chain, including securing adequate supply of critical components necessary for manufacturing and assembly.
• Risks associated with successful FDA inspections of the company's facilities and those of its third-party suppliers/manufacturers.
• Challenges in successfully implementing and managing the HEPZATO KIT Risk Evaluation and Mitigation Strategy.
• Uncertainties regarding the company's ability to obtain reimbursement for the HEPZATO KIT.
• Risks related to the company's ability to successfully enter into any necessary purchase and sale agreements with users of the HEPZATO KIT.
• The potential for new risk factors and uncertainties to emerge from time to time.

Future Outlook

Delcath Systems updated its full-year 2025 financial guidance, projecting total CHEMOSAT and HEPZATO KIT revenue in the range of $93 million to $96 million, an increase of over 150% from 2024. The company also anticipates gross margins between 83% and 85% and expects to achieve positive adjusted EBITDA and cash flow in each quarter of 2025.

Management Comments

• The consistent utilization of HEPZATO at treating sites and continued positive feedback from treating physicians has increased our confidence in HEPZATO’s long term growth prospects.
• Physicians are sharing positive results, which is expanding interest at sites not yet activated as well as interest in participating in the future development of HEPZATO.
• With growing physician engagement and a strong financial outlook, the company is well prepared to pursue additional indications for HEPZATO.

Industry Context

Delcath operates in the interventional oncology space, specifically targeting primary and metastatic liver cancers with its unique drug-device combination. The strong revenue growth and shift to profitability suggest successful market penetration and adoption of HEPZATO KIT, positioning the company favorably within the niche but growing liver cancer treatment market. The expansion into new clinical indications (metastatic colorectal cancer, metastatic breast cancer) indicates a strategy to broaden the addressable market beyond metastatic uveal melanoma, aligning with broader trends in oncology to find more targeted and effective treatments for difficult-to-treat cancers.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to benchmark against. However, achieving positive net income and adjusted EBITDA, along with significant revenue growth (over 150% projected for the full year), is generally indicative of strong performance for a specialized biotech/med-device company, especially one commercializing a newly approved product like HEPZATO KIT.
• The gross margin of 86% is exceptionally high, suggesting strong pricing power and/or efficient production for a specialized medical product, which compares favorably to many pharmaceutical or medical device companies that often have gross margins in the 60-80% range.

Stakeholder Impact

• Shareholders: Positive impact due to strong financial performance, profitability, positive cash flow, and optimistic future guidance, potentially leading to increased share value.
• Patients: Expanded access to HEPZATO KIT through increased active centers and the planned Medicaid NDRA, as well as potential future indications from ongoing clinical trials.
• Employees: Increased headcount in clinical and commercial teams suggests job growth and stability.
• Healthcare Providers/Treating Sites: Increased utilization and positive feedback from physicians indicate successful adoption and clinical utility of HEPZATO.

Next Steps

• Continue commercialization of HEPZATO KIT.
• Manage HEPZATO KIT supply chain, including securing adequate supply of critical components.
• Implement and manage HEPZATO KIT Risk Evaluation and Mitigation Strategy.
• Obtain reimbursement for the HEPZATO KIT.
• Enter into necessary purchase and sale agreements with users of the HEPZATO KIT.
• Pursue additional indications for HEPZATO, including Phase 2 clinical trials for metastatic colorectal cancer and metastatic breast cancer.
• Enter into a Medicaid National Drug Rebate Agreement (NDRA) starting July 1, 2025.

Key Dates

Recommendation

The company has demonstrated a significant turnaround, moving from substantial losses to profitability and positive cash flow, driven by robust revenue growth of its key product, HEPZATO KIT. The updated full-year guidance projects over 150% revenue growth and sustained profitability. With a strong cash position and no debt, coupled with expansion into new treatment centers and new clinical indications, the company is well-positioned for continued growth and market penetration in a specialized oncology segment. The high gross margins further underscore the product's value proposition. While R&D and SG&A expenses are increasing, this is directly tied to growth initiatives and clinical expansion, which are positive long-term investments.

Keywords

Delcath Systems, DCTH, interventional oncology, liver cancer, HEPZATO KIT, CHEMOSAT, melphalan, metastatic uveal melanoma, mUM, hepatic metastases, percutaneous hepatic perfusion, PHP, financial results, Q2 2025, revenue, EBITDA, clinical trials, Medicaid, FDA, Nasdaq